Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | PTPRC | P08575 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918267 | 0.89 | MAPK14 (0.55) | AKR1B1TDP1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL3142640 | 0.87 | MAPT (0.72) | TDP1L3MBTL1ALDH1A1MAPTRAB9A | |
| SCHEMBL9977361 | 0.86 | MAOA (0.47) | AKR1B1TDP1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL7246016 | 0.86 | TDP1 (0.64) | AKR1B1TDP1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL4222122 | 0.82 | MAPK14 (0.66) | MAPK14 | |
| Phenol SCHEMBL9561887 | 0.82 | MAPT (0.57) | AKR1B1TDP1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL29375440 | 0.81 | MAPT (0.67) | AKR1B1TDP1ALDH1A1MAPTRAB9A | |
| SCHEMBL86392 | 0.81 | MAPT (0.67) | AKR1B1TDP1ALDH1A1MAPTRAB9A | |
| SCHEMBL3098370 | 0.81 | MAPK14 (0.68) | AKR1B1TDP1ALDH1A1MAPTRAB9A | |
| SCHEMBL11575938 | 0.81 | MAPK14 (0.68) | AKR1B1TDP1ALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-8653096-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | disclosed |
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | disclosed |
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | disclosed |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R (US) | 2012-04-19 | — | — | US | disclosed |
| EP-0497201-A1 | Tricyclic compounds and intermediates thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
| EP-0487502-A2 | Pharmaceutically active aryl-substituted amine derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-05-27 | — | — | EP | disclosed |
| EP-0409406-A2 | Aryl-substituted amine derivatives useful in cancer therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-01-23 | — | — | EP | disclosed |
| WO-1990015599-A1 | MEDICAMENTS USEFUL IN CANCER THERAPY AND HAVING ANTIHISTAMINIC PROPERTIES | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-12-27 | — | — | WO | disclosed |
| US-4923892-A | DOXEPIN DERIVATIVES; ANTIALLERGENS, ANTIASTHMATICS, ANTIHISTAMINES | BURROUGHS WELLCOME CO. (US) | 1990-05-08 | — | — | US | disclosed |
| EP-0214779-B1 | TRICYCLIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-04-11 | — | — | EP | disclosed |
| EP-0351887-A1 | Tricyclic aromatic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-24 | — | — | EP | disclosed |
| US-4871865-A | ANTIHISTAMINES | BURROUGHS WELLCOME CO. (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0316022-A2 | Tricyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-05-17 | — | — | EP | disclosed |
| EP-0214779-A1 | Tricyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | AKR1B1 628/4885TDP1 3925/4885L3MBTL1 2619/4885 |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | AKR1B1 651/4885TDP1 3547/4885L3MBTL1 4007/4885 |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | AKR1B1 651/4885TDP1 3547/4885L3MBTL1 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.